
Lyudmila Bazhenova, MD, of UC San Diego Moores Cancer Center, asks Pasi A. Jänne, MD, PhD, of Dana-Farber Cancer Institute, about sunvozertinib in previously treated EGFR exon 20 insertion–mutated non–small cell lung cancer, where it is approved based on WU-KONG1B and carries a National Comprehensive Cancer Network Category 2A listing but is not yet available.














